ViiV Healthcare Receives EC's Marketing Authorisation of Triumeq PD for the Treatment of Human Immunodeficiency Virus Type 1
Shots:
- The company received marketing authorization from the EC for Triumeq PD to treat paediatric patients with HIV-1. The authorization also includes the label extension of Triumeq & lowers the minimum weight of a child who can be prescribed this medicine to 25kgs from 40 kg
- The authorization was based on the US FDA’s approval of Triumeq PD in 2022. In 2021, 52% of children aged ≤14yrs. living with HIV had access to antiretroviral medications with paediatric optimizations.
- Triumeq is a dispersible tablet formulation of the fixed-dose combination of abacavir, dolutegravir, and lamivudine for the treatment of paediatric patients with HIV-1
Ref: ViiV Healthcare | Image: ViiV Healthcare
Related Post:- ViiV Healthcare Presents Five-Year P-III (BRIGHTE) Study Results of Fostemsavir for Multidrug-Resistant HIV-1 Infection at AIDS 2022
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
